Sign in
Enrolling by invitationNo phase

Studying blood and tumor samples from people with chest cancers

Studies samples from blood and tumors in people with thoracic cancers.

Key facts

Who runs it
Stanford University
Where
Stanford, United StatesSee the site
Trial code
Registry title
Molecular Analysis of Thoracic Malignancies
Status
Enrolling by invitation
People taking part
1,000 people, planned
Started
Aug 2011
Expected to end
Jun 2031
Type of study
Observational
Record updated
26 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a proven chest cancer, such as lung cancer, thymoma, thymic carcinoma or mesothelioma. It studies blood, tumor tissue and other fluids.

Age
18 years or older
Sex
Men and women can join
Disease stage
Proven non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, mesothelioma, or carcinoma of unknown primary consistent with a primary thoracic malignancy

Main reasons for not taking part

  • Not able to understand and sign a written informed consent document
  • Not willing to sign a written informed consent document

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • 1.Histologically proven diagnosis of non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, mesothelioma, or carcinoma of unknown primary consistent with the presentation of a primary thoracic malignancy
  • 2.18 years of age or older
  • 3.Ability to understand and the willingness to sign a written informed consent document

Where in United States

  • Stanford University School of MedicineStanford, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

A research study to learn about the biologic features of cancer development, growth, and spread. We are studying components of blood, tumor tissue, normal tissue, and other fluids, such as urine, cerebrospinal fluid, abdominal or chest fluid in patients with cancer. Our analyses of blood, tissue, and/or fluids may lead to improved diagnosis and treatment of cancer by the identification of markers that predict clinical outcome, markers that predict response to specific therapies, and the identification of targets for new therapies.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Molecular Analysis of Thoracic Malignancies
Plain-language title
Studying blood and tumor samples from people with chest cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 December 2025